CellaVision AB engages in the provision of digital microscopy solutions for hematology laboratories. The company is headquartered in Lund, Skane and currently employs 228 full-time employees. The company went IPO on 2007-05-28. The firm develops and sells digital solutions for medical microscopy, as well as products enabling blood cell analysis and morphology diagnosis. CellaVision AB’s product portfolio consists of analyzers for automated medical microscopy analysis and software applications designed for remote access, competency testing and education. The analyzers include such brands as CellaVision DM96 and CellaVision DM1200, whereas the software applications are divided into CellaVision Body Fluid Application, CellaVision Remote Review Software and CellaVision Competency Software, among others. The firm operates four subsidiaries, based in Sweden, Canada, the United States and Japan. In June 2014, CellaVision AB acquired technology platform from Clear Lake Medical Foundation.
Follow-Up Questions
CLVSF の株価パフォーマンスは？
CLVSF の現在の価格は $0 で、最終取引日から 0% decreased 変動しました。
CellaVision AB の主な事業テーマや業界は？
CellaVision AB は Health Care 業界、セクターは Health Care に属しています。
